The Consortium for Clinical Research and Innovation, Singapore (CRIS) was established in 2020 with the goal of strengthening synergies and developing strategies for national-level clinical research and translation programmes that are under the stewardship of the Ministry of Health. It is a subsidiary of the Ministry of Health Holdings (MOHH).
CRIS brings together six key national R&D initiatives and clinical services, and facilitate synergistic collaborations among them. These initiatives include:
- Singapore Clinical Research Institute (SCRI)
- National Health Innovation Centre Singapore (NHIC)
- Advanced Cell Therapy and Research Institute, Singapore (ACTRIS)
- Precision Health Research, Singapore (PRECISE)
- Singapore Translational Cancer Consortium (STCC)
- Cardiovascular Disease National Collaborative Enterprise (CADENCE)
CRIS aims to make a positive difference to Singapore patients and researchers by ensuring that these clinical research platforms and programmes are at the cutting edge of capability development and innovation. This will be achieved through facilitated collaborations and enduring partnerships with research and biomedical entities and communities across the public sector and industry across Singapore.
To nurture and build for Singapore, cutting-edge capabilities and innovation in clinical research and translation.
To ensure unity of mission across research platforms and programmes under the CRIS stable.
To ensure synergies of capabilities, scientific resources, industry development and finances across research platforms and programmes.
To ensure that the platforms and programmes stay relevant and are aligned to the needs of Singapore patients, researchers and industry through constant and regular stakeholder engagement.
To build, review and sustain long term strategies for research platforms and programmes.